Ana Corachán: “Our goal is to improve efficacy in uterine fibroid treatment through personalized therapy.”

Ana Corachán is a former student of the Master in Biotechnology of Assisted Human Reproduction and postdoctoral researcher in the Treatment and Diagnosis of Uterine Diseases Research Group at Fundación IVI, which she joined 5 years ago after completing her doctoral thesis. After finishing the thesis, the Generalitat Valenciana (APOSTD) granted her a postdoctoral contract to continue her research in this group where she works "seeking to increase the efficacy of treatment of uterine fibroids through personalized therapy".

The researcher is one of the five IVI researchers to be awarded a grant by the Instituto de Salud Carlos III (ISCIII) following the results of the Strategic Action in Health 2020 call for proposals. "With the economic aid provided by this grant, we will be able to study the differences between uterine fibroids that present mutation in the MED12 and those that do not as well as the pathogenesis and their response to treatment with Vitamin D,” explains Ana. “This will help us to determine this treatment’s effectiveness in different types of fibroids which would allow us to use it in the majority of women who suffer this disease or if, on the contrary, each needs to be treated in an individualized manner,” adds the researcher.


The importance of specialized training in research

Ana Corachán is a Biologist by training, and assisted reproduction was always one of the top options in her professional future. She joined IVI through our official master's degree with the University of Valencia which [in her own words] “gave her the opportunity to learn first-hand how assisted reproduction laboratories and research laboratories work while acquiring both theoretical and practical knowledge of reproductive medicine and recognizing the high level of specialization required in this area of work.” Ana is currently involved in the continuation of the last stage of a research project that she had been working on to find treatments to safely reduce uterine fibroids in patients without negatively affecting fertility.


An international legacy

The researcher's project has an estimated duration of 2 years, including a 12-month stay at the University of Chicago, where part of the research will be conducted.

Until now, uterine fibroids have been treated as a single entity. Corachán's project now focuses on the stratification of these tumors according to their mutations. This new focus would allow individualized therapy that would increase the efficacy of treatments and consequently improve the quality of life of patients throughout the world, given that fertility is an issue of concern in most societies.

We share?

    Leave a Reply

    Your email address will not be published. Required fields are marked *